Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

34.32EUR
11:35am EDT
Change (% chg)

€0.10 (+0.29%)
Prev Close
€34.22
Open
€34.38
Day's High
€34.70
Day's Low
€33.78
Volume
97,949
Avg. Vol
126,581
52-wk High
€86.64
52-wk Low
€32.88

Chart for

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.26
Market Cap(Mil.): €1,035.33
Shares Outstanding(Mil.): 29.80
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 28.95 33.54
EPS (TTM): -5.97 -- --
ROI: -73.78 13.56 13.09
ROE: -79.24 15.37 15.10

BRIEF-DBV Technologies Reports Cash position of 234.5 Million Euros at end March

* CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018, WERE EUR 234.5 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 27 2018

BRIEF-DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering

* REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING

Mar 26 2018

BRIEF-DBV Technologies Announces Pricing Of 122.5 Million Euros Global Offering Of Ordinary Shares

* ANNOUNCES PRICING OF $150.0 MILLION (EUR 122.5 MILLION) GLOBAL OFFERING OF ORDINARY SHARES

Mar 21 2018

BRIEF-DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​

* DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES

Mar 20 2018

BRIEF-DBV Technologies FY Net Loss widens to 147.7 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 EUR 137.9 MILLION VERSUS EUR 256.5 MILLION YEAR AGO

Mar 14 2018

BRIEF-DBV Technologies Announces Result From Phase II Study of Viaskin Milk

* ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

Feb 27 2018

BRIEF-DBV Technologies Announces Results From Phase II Study Of Viaskin Milk In Milk-Allergic Patients

* DBV TECHNOLOGIES ANNOUNCES RESULTS FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

Feb 26 2018

BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros

* ‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 20 2018

BRIEF-Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut

* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT

Feb 14 2018

Earnings vs. Estimates